Brief: Kiromic Biopharma Receives Notice Of Delisting From Nasdaq
30/11/2022 21:23
Nov 30 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* ON NOV 23, CO RECEIVED NOTICE OF DELISTING OR FAILURE TO
SATISFY
A CONTINUED LISTING RULE OR STANDARD FROM NASDAQ
Source text for Eikon: ID:
Further company coverage: KRBP.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site